Member Info for Laura2022

Given the tempo of activity during the holiday season across the Company's activities, notably in DRC but also in Burkina Faso where we are moving towards gold production and travel plans have been affected by illness of two key personnel, we are grateful for the agreement of the vendors in Australia in adjusting the timing of one element of the consideratio

Something is happening

Again

1.40 to buy and 1.41 to sell lol

I was too early at 2.4p+ but added more down here

That sell looks like last of an II

With buyer taking blocks

Added another £1k

To show

140k buys but just 25k sells but they mark it down

Buy

And more

He likes talking to himself

X

Current shares in issue 4mln

New shares 18mln

That's some dilution

Nice green boxes

I assume it's the other oddball kabaa who won't answer single questiosn about NAPS/EVRH

If that the case KingH

It makes a mockery of current £1.4mln market value of PYC

And beyond blood ha just a fraction of the clients/tech PYC ha developed over the last few years

It suggests PYC should be £10mln-20mln surely?

Many thanks De bull

The New Ordinary Shares will be issued at a price of 5 pence per New Ordinary Share (the "Issue Price").

The total amount that the Company could raise under the Subscription and the Retail Offer (together, the "Fundraise") is £1,030,000 (before expenses), all of which will be used for the Company's working capital purposes.

Team!

Thankfully looks like LSE have banned the 3rd re incarnation of Neil777

Thanks Debull

Does this suggest FDA is expanding its tram in light of these new guidances from them ?

Machine Learning, Artificial Intelligence and Computational Modeling

1293 Establishing the preclinical PKPD relationship for NM32–2668 a ROR1 targeting T cell engager FREE

Hitesh Mistry1, Fernando Ortega1, Bithi Chatterjee2, Nicole Bassler2, Niels Kirk2, Julia Tietz2, Belinda Wickihalder2, Simone Muntwiler2, Simon Carnal2, Daniel Snell2 and Christophe Chassagnole1

Abstract

Background NM32-2668 is a fragment-based multispecific antibody therapeutic1 that has been designed to activate T-cells (via CD3) in the presence of tumour antigen receptor tyrosine kinase-like orphan receptor 1 (ROR1). The objective of this work was to build a mathematical model to establish a PKPD relationship using both in vitro and in vivo data for NM32-2668.